Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice (BIO-FIL_MAB)

August 11, 2026 updated by: Fondazione Italiana Linfomi - ETS

Multilayer Biological Analysis of Novel Monoclonal Antibodies (MABs) in B-Cell Non-Hodgkin Lymphoma (NHL): A Translational and Prospective Observational Study Within Italian Clinical Practice (BIO-FIL_MAB Trial)

This a prospective, multicenter, observational pharmacological translational study designed to investigate the biological and imaging correlates of treatment with novel monoclonal antibodies (NMABs) in patients with B-cell non-Hodgkin lymphoma (NHL), enrolled in the observationa FIL_MAB study. Patients enrolled in BIO FIL-MAB are concurrently participating in the FIL-MAB clinical cohort, ensuring that all clinical data-including treatment details, outcomes, and safety-are captured within the main observational study.

Patients will undergo systematic collection of biological specimens including tumor tissue, peripheral blood integrated with advanced imaging data. Biological analyses will encompass molecular, cellular, and immunological assessments, while imaging evaluations will include standardized functional and metabolic imaging techniques. All biological and imaging assessments will be performed as routine clinical visits, without requiring modifications to treatment or additional procedures beyond standard-of-care.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This a prospective, multicenter, observational pharmacological translational study designed to investigate the biological and imaging correlates of treatment with novel monoclonal antibodies (NMABs) in patients with B-cell non-Hodgkin lymphoma (NHL), enrolled in the observational FIL_MAB study.

All clinical observations, including baseline characteristics, treatment exposure, and follow-up, are collected through the FIL-MAB study database, with a minimum follow-up of 60 months (5 years) from enrollment and correlated with biological findings for translational analysis performed in BIO-FIL_MAB study.

The BIO-FIL_MAB study will employ a structured schedule of biological and imaging assessments to monitor treatment outcomes and gather translational data. The timeline will be aligned with routine clinical practice:

  • Prior to NMAB Treatment
  • During NMAB Therapy (3 months after start of therapy, 9 months after start of therapy, progression/relapse).

This structured schedule ensures a comprehensive evaluation of both clinical and biological treatment effects, aligning with the study's translational objectives.

As an observational translational study primarily intended for descriptive and exploratory analyses, no formal statistical hypothesis testing is planned.

Therefore, the sample size has been determined based on feasibility considerations and the expected availability of patients participating in the parent FIL-MAB clinical cohort, thereby ensuring a robust population for integrated biological, immunological, and imaging analyses in association with clinical outcomes.

Overall, it is anticipated that at least 1000 patients will be consecutively enrolled and followed longitudinally in BIO-FIL_MAB study.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Italy
      • Alessandria, Italy, 15121
        • SCDU Ematologia -AOU SS. Antonio e Biagio e Cesare Arrigo di Alessandria
        • Contact:
      • Aviano, Italy, 33081
        • Divisione di Oncologia e dei Tumori immuno-correlati - IRCCS Centro di Riferimento Oncologico di Aviano
        • Contact:
      • Bari, Italy, 70124
      • Bergamo, Italy, 24127
        • SC Ematologia - Azienda Ospedaliera Papa Giovanni XXIII - Bergamo
        • Contact:
      • Bologna, Italy, 40138
      • Brescia, Italy, 25123
      • Cuneo, Italy, 12100
      • Florence, Italy, 50141
      • Milan, Italy, 20133
        • Ematologia - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
        • Contact:
      • Milan, Italy, 20162
      • Novara, Italy, 28100
      • Pescara, Italy, 65124
        • UOC Ematologia Dipartimento Oncologico Ematologico - P.O. Spirito Santo di Pescara - ASL Pescara
        • Contact:
      • Reggio Emilia, Italy, 42123
        • Ematologia - Arcispedale Santa Maria Nuova - IRCCS -Azienda Unità Sanitaria Locale
        • Contact:
      • Roma, Italy, 00161
        • Dipartimento di Medicina Traslazionale e di Precisione - Istituto Ematologia - Policlinico Umberto I - Università "La Sapienza" - Roma
        • Contact:
      • Torino, Italy, 10126
        • Ematologia Universitaria - A.O.U. Città della Salute e della Scienza di Torino
        • Contact:
      • Torino, Italy, 10126
      • Verona, Italy, 37134
        • U.O. Ematologia - AOU Integrata di Verona
      • Vicenza, Italy, 36100
    • Torino
      • Candiolo, Torino, Italy, 10060
        • Ematologia - Fondazione del Piemonte per l'Oncologia - IRCCS
        • Contact:
    • Treviso
      • Castelfranco Veneto, Treviso, Italy, 31033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Being an observational translational study primarily aimed at descriptive and exploratory analyses, no formal statistical hypothesis testing is planned for BIO-FIL_MAB. The sample size is therefore determined based on feasibility and the expected availability of patients participating in the parent FIL-MAB clinical cohort. Overall, it is anticipated that at least 1000 patients will be enrolled and followed, providing a robust population for integrated biology, immunology, and imaging analyses alongside clinical outcomes.

Description

Inclusion Criteria:

  • Adults (≥18 years old) are diagnosed with B-cell Non-Hodgkin Lymphoma;
  • Patients enrolled in the FIL_MAB trial (provided by Informed Consent Form (ICF) signature) who are scheduled to receive treatment with novel monoclonal antibodies (NMABs), either as monotherapy or in combination with other therapies;
  • Written informed consent to participate in this study.

Exclusion Criteria:

  • Patients not enrolled in the FIL_MAB study.

  • Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

    • Uncontrolled and/or active systemic infection (viral, bacterial or fungal), including active ongoing infection from SARSCoV-2;
    • Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous infection or intravenous immunoglobulins (IVIG) may participate; inactive carriers (HBsAg positive with undetectable HBV- DNA) are eligible. Patients with presence of HCV antibody are eligible only if PCR negative for HCV-RNA;
    • HIV seropositivity;
  • Refusal or inability to provide informed consent.
  • Refusal or inability to provide biological specimens.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
T-cell engager antibodies - Work package 1 (WP 1)
WP1 includes all the FIL-MAB-approved cohorts related to novel T-cell engager therapies (e.g. bi-specifics and others).
Other: WP1 - Task 1 - Liquid analyses

Objectives

  1. To investigate the value of circulating tumor DNA (ctDNA)/ Minimal Residual Disease (MRD) status as prognostic biomarker for B-NHL patients treated with commercial bi-specifics antibodies (bsAbs).
  2. To evaluate the potential role of clonal hematopoiesis (CH) in terms of therapy-related toxicities and treatment response.
  3. To evaluate the potential prognostic role of germline single-nucleotide polymorphisms (SNPs) involved in drug metabolic pathways and cell-to-cell interactions.
Other: WP1 - Task 2 - Immunological analyses

Objectives

  1. evaluate association between levels and subtypes of T cell in PB before and after bsAbs with COs.
  2. Analyze expression of PD1, CD25, 41BB/CD137, CTLA4, CD28, and other T cell co-stimulatory molecules, and correlate with COs.
  3. Evaluate expansion of NK cells along with their markers of activation, exhaustion, maturation, chemotaxis.
  4. evaluate association between T cell exhaustion with treatment failure.
  5. evaluate association between T cell exhaustion with previous lines of treatment or other clinical factors such as relapsed time.
  6. evaluate association between T cell clusters with the development of cytopenia during treatment.
  7. investigate whether immunosenescence (composition and activation status of PBMCs) and inflammaging (soluble mediators) can predict response and clinical outcomes in elderly patients (≧70) undergoing treatment with bsAbs.
  8. Immunological characterization of T cell subset by bulk RNAseq before and after bsAbs with COs.
Other: WP1 - Task 3 - Tumor tissue analyses

Objectives

  1. Association between specific mutational (Whole Genome Sequencing, WGS) and transcriptomic (Whole Transcriptome Sequencing, WTS) patterns with disease response to bsAbs therapy.
  2. To investigate TP53 mutation and del17p as predictive factor of response to bsAbs.
  3. Identifying specific relapse patterns, with the hypothesis that alterations in tumor genes facilitating immune evasion are enriched in clones emerging at relapse (i.e., secondary resistance).
  4. To characterize intratumoral immune effector cell distribution and to assess T-cell functional fitness and exhaustion states within tumor-draining lymph nodes using Digital Spatial Profiling (DSP).
  5. To investigate the association between bsAbs surface target antigens (e.g. CD20) expression level and response to bsAbs.
Other: WP1 - Task 4 - Imaging analyses

Objectives

  1. explore how tumor metabolic activity signature predict prognosis and treatment response during bsAbs-approved treatments.
  2. explore how tumor heterogeneity activity predicts prognosis and treatment response during bsAbs -approved treatments.
  3. explore how PET findings are integrated with other biomarkers, we refine predictions of prognosis and treatment efficacy during bsAbs-approved treatments.
  4. explore novel prognostic markers of progression in CT scans and PET scans.
  5. apply advanced artificial intelligence methods (radiomics and deep learning) for automated extraction of complex imaging features from PET/CT scans, aiming to enhance prediction of prognosis and treatment response in patients undergoing bsAbs-approved treatments.
  6. develop and validate AI-driven multimodal integration frameworks that combine imaging data with clinical and molecular biomarkers, refining risk stratification and enabling early detection of progression under bsAbs therapy.
Other: WP1 - Task 5 - Microbiome and metabolomics analyses

Objectives

  1. To describe plasma and tissue microbiome composition and metabolomics during bsAbs -approved treatments.
  2. To investigate whether microbiome/metabolomics predicts outcomes during bsAbs -approved treatments.
  3. To investigate whether microbiome/metabolomics predicts treatment toxicity during bsAbs -approved treatments.
Immunoconjugates antibodies - Work package 2 (WP2)
WP2 includes all the FIL-MAB-approved cohorts related to novel immunoconjugate therapies (e.g. Antibody-Drug Conjugates (ADCs)).
Other: WP2 - Task 1 - Liquid analyses

Objectives

  1. To identify and validate biological and molecular biomarkers (i.e. ctDNA/MRD) that predict patient outcomes in patients treated with novel immunoconjugate therapies.
  2. To evaluate the potential role of clonal hematopoiesis (CH) in terms of therapy-related toxicities and treatment response.
  3. To evaluate the potential prognostic role of germline single-nucleotide polymorphisms (SNPs) involved in drug metabolic pathways and cell-to-cell interactions.
Other: WP2 - Task 2 -Immunological analyses

Objectives

  1. evaluate the association between levels and subtypes of T cells in PB before and after ADCs with COs.
  2. Analyze the expression of PD1, CD25, 41BB/CD137, CTLA4, CD28, and other T cell co-stimulatory molecules, and correlate them with COs.
  3. Evaluate the expansion of NK cells along with their markers of activation, exhaustion, maturation, chemotaxis.
  4. evaluate the association between T cell exhaustion with treatment failure.
  5. evaluate the association between T cell exhaustion with previous lines of treatment or other clinical factors such as relapsed time.
  6. evaluate the association between T cell clusters with the development of cytopenia during treatment.
  7. investigate whether immunosenescence and inflammaging can predict response and clinical outcomes in elderly patients (≧ 70) undergoing treatment with ADCs.
  8. Immunological characterization of T cell subset by bulk RNAseq before and after ADCs with clinical outcomes.
Other: WP2 - Task 3 - Tumor tissue analyses

Objectives

  1. characterize intratumoral immune effector cell distribution and assess T-cell functional fitness and exhaustion states within tumor-draining lymphnodes using DSP.
  2. investigate correlation between ADCs surface target antigens expression level and response to ADCs treatment
  3. investigate MYC translocation alone or in association with BCL2 and or BCL6 translocation or other MYC chromosomal aberrations as predictive factors of response to ADCs assessed by FISH on diagnostic biopsy and last biopsy preADCs treatment.
  4. investigate TP53 mutation and del17p as predictive factor of response to ADCs.
  5. investigate mutations and CNVs as predictive factors of response to ADCs treatment.
  6. investigate ADCs target antigens RNA expression level and correlation with response to ADCs treatment.
  7. characterize transcriptomic and sRNA landscapes to identify gene expression signatures and microRNA profiles associated with response to ADCs treatment.
Other: WP2 - Task 4 - Imaging analyses

Objectives

  1. explore how tumor metabolic activity signature predict prognosis and treatment response during ADCs-approved treatments.
  2. explore how tumor heterogeneity activity predicts prognosis and treatment response during ADCs-approved treatments.
  3. explore how PET findings are integrated with other biomarkers, we refine predictions of prognosis and treatment efficacy during ADCs-approved treatments.
  4. explore novel prognostic markers of progression in CT scans and PET scans.
  5. apply advanced artificial intelligence methods (radiomics and deep learning) for automated extraction of complex imaging features from PET/CT scans, aiming to enhance prediction of prognosis and treatment response in patients undergoing ADCs-approved treatments.
  6. develop and validate AI-driven multimodal integration frameworks that combine imaging data (PET/CT) with clinical and molecular biomarkers, refining risk stratification and enabling early detection of progression under ADCs therapy.
Other: WP2 - Task 5 - Microbiome and metabolomics analyses

Objectives

  1. To describe plasma and tissue microbiome and metabolomics composition during ADCs-treatments.
  2. To investigate whether microbiome/metabolomics predicts outcomes during ADCs-approved treatments.
  3. To investigate whether microbiome/metabolomics predicts treatment toxicity during ADCs-approved treatments.
Naked antibodies - Work package 3 (WP3)
WP3 includes all the FIL-MAB-approved cohorts related to novel naked antibodies- based therapies.
Other: WP3 - Task 1 - Liquid analyses

Objectives

  1. To identify and validate biological and molecular biomarkers (i.e. ctDNA/MRD) that predict patient outcomes in patients treated with novel naked antibodies.
  2. To evaluate the potential role of clonal hematopoiesis (CH) in terms of therapy-related toxicities and treatment response.
  3. To evaluate the potential prognostic role of germline single-nucleotide polymorphisms (SNPs) involved in drug metabolic pathways and cell-to-cell interactions.
Other: WP3 - Task 2 - Immunological analyses

Objective

1) Evaluate the expansion of immunological cells along with their markers of activation, exhaustion, maturation, and chemotaxis.

Other: WP3 - Task 3 - Tumor tissue analyses

Objectives

  1. To investigate the correlation between naked antibodies surface target antigens (e.g. CD19) expression level and response to naked antibodies.
  2. To investigate MYC translocation alone or in association with BCL2 and or BCL6 translocation, or other MYC chromosomal aberrations as predictive factors of response to naked antibodies (assessed by FISH on diagnostic biopsy and last biopsy pre- naked antibodies).
  3. To investigate TP53 mutation and del17p as predictive factor of response to naked antibodies.
  4. To investigate mutations and copy number variations (CNVs) (either studied by targeted sequencing or by WES) as predictive factors of response to treatment.
Other: WP3 - Task 4 - Imaging analyses

Objectives

  1. explore how tumor metabolic activity signature predict prognosis and treatment response during naked Abs-approved treatments.
  2. explore how tumor heterogeneity activity predicts prognosis and treatment response during naked Abs-approved treatments.
  3. explore how PET findings are integrated with other biomarkers, we refine predictions of prognosis and treatment efficacy during naked Abs-approved treatments.
  4. explore novel prognostic markers of PD in CT and PET scans.
  5. apply advanced artificial intelligence methods (radiomics and deep learning) for automated extraction of complex imaging features from PET/CT, aiming to enhance prediction of prognosis and treatment response in patients undergoing naked Abs-approved treatments.
  6. develop and validate AI-driven multimodal integration frameworks that combine imaging data with clinical and molecular biomarkers, refining risk stratification and enabling early detection of progression under naked Abs therapy.
Other: WP3 - Task 5 - Microbiome and metabolomics analyses

Objectives

  1. To describe plasma and tissue microbiome and metabolomics composition during naked antibodies -approved treatments.
  2. To investigate whether microbiome/metabolomics predicts outcomes during naked antibodies -approved treatments.
  3. To investigate whether microbiome/metabolomics predicts treatment toxicity during naked antibodies -approved treatment.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
1) Association between MRD status and Progression Free Survival (PFS).
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
2) Association between MRD status and Overall Survival (OS).
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
3) Association between between MRD status and clinical response.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
4) Comparison between MRD negativity rates obtained by different BsAbs time to obtain MRD negativity by different BsAbs.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
5) Correlation between baseline ctDNA levels and outcome (response, PFS, OS).
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
6) Association between MRD status and other clinical and biological prognostic markers (e.g. mutational patterns, T-cell phenotypes).
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
7) Association between baseline ctDNA and MRD with imaging biomarkers (Total Metabolic Tumor Value (TMTV), Maximum Tumor Dissemination (Dmax), Standardized Uptake Value maximum (SUVmax), Artificial Intelligence (AI) features etc).
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
8) Association of CH with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
9) Association of SNPs with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
1) Quantification of CD4+ and CD8+T lymphocyte clusters and soluble mediators of inflammagin, at baseline, month +3 (M3) and End Of Treatment (EOT), and correlation with clinical outcome (PFS, OS).
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
2) Measuring NK cells count at baseline and M3 and correlation with outcome.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
3) Association between CD4+ Treg, CD4+, and CD8+ T lymphocyte counts at M3 and Complete Metabolic Response (CMR)/MRD-.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
4) Association between CD4+ Treg, CD4+, and CD8+ T Lymphocyte counts at M3 and 2-Y PFS.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
5) Expression of co-stimulatory molecules such as PD1, CD25, 41BB/CD137, CTLA4, and CD28 on T cells at M3 and their correlation with achieving a CMR.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
6) Correlation between T cell exhaustion and treatment failure.
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
7) Correlation of T lymphocyte clusters and soluble mediators of inflammaging with safety (e.g. Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), infections).
from enrollment start to final analyses (15 years)
T-cell engager antibodies - Work package (WP 1) - Task 3 - Tumor tissue analyses
Time Frame: from enrollment start to final analyses (15 years)
  1. Correlation of specific mutational profiles with Overall Response Rate (ORR) rates, 2-Y PFS and 2-Y OS.
  2. Correlation of specific transcriptomic signatures with ORR rates, 2-Y PFS and 2-Y OS.
  3. Correlation of intra-tumoral T-cell populations and non-T-cell populations with ORR rates, 2-Y PFS and 2-Y OS.
  4. Identifying specific relapse patterns, with the hypothesis that alterations in tumor genes facilitating immune evasion are enriched in clones emerging at relapse (i.e., secondary resistance).
  5. Correlation between target antigen surface level (i.e. CD20) with ORR rates, 2-Y PFS and 2-Y OS.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
1) Association between MRD status and PFS.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
2) Association between MRD status and OS.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
3) Association between MRD status and clinical response.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
4) Comparison between MRD negativity rates obtained by different BsAbs time to obtain MRD negativity by different BsAbs.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
5) Correlation between baseline ctDNA levels and outcome (response, PFS, OS).
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
6) Association between MRD status and other clinical and biological prognostic markers (e.g. mutational patterns, T-cell phenotypes).
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
7) Association between baseline ctDNA and MRD with imaging biomarkers (TMTV, Dmax, SUVmax, AI features etc).
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
8) Association of CH with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
9) Association of SNPs with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
1) Quantification of CD4+ and CD8+T lymphocyte clusters and soluble mediators of inflammagin, at baseline, month +3 (M3) and EOT, and correlation with clinical outcome (PFS, OS).
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
2) Measuring NK cells count at baseline and M3 and correlation with outcome.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
3) Association between CD4+ Treg, CD4+, and CD8+ T lymphocyte counts at M3 and CMR/MRD-.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
4) Association between CD4+ Treg, CD4+, and CD8+ T Lymphocyte counts at M3 and 2-Y PFS.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
5) Expression of co-stimulatory molecules such as PD1, CD25, 41BB/CD137, CTLA4, and CD28 on T cells at M3 and their correlation with achieving a CMR.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
6) Correlation between T cell exhaustion and treatment failure.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses
Time Frame: from enrollment start to final analyses (15 years)
7) Correlation of T lymphocyte clusters and soluble mediators of inflammaging with safety (e.g. infections).
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 3 - Tumor tissue analyses
Time Frame: from enrollment start to final analyses (15 years)
1) Association between target antigen surface level and CRR with ADCs treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before ADCs treatment.
from enrollment start to final analyses (15 years)
Immunoconjugates antibodies - Work package 2 (WP2) Task 3 - Tumor tissue analyses
Time Frame: from enrollment start to final analyses (15 years)
2) Association between target antigen surface level and OS, PFS and ORR with ADCs treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before ADCs treatment and correlation with biological and imaging predictors. Correlation of CH with PFS, OS and therapy-related toxicities and correlation of SNPs with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
1) Association between MRD status and PFS.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
2) Association between MRD status and OS.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
3) Association between MRD status and clinical response.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
4) Comparison between MRD negativity rates obtained by different naked antibodies time to obtain MRD negativity by different naked antibodies.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
5) Correlation between baseline ctDNA levels and outcome (response, PFS, OS).
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
6) Association between MRD status and other clinical and biological prognostic markers (e.g. mutational patterns, T-cell phenotypes).
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
7) Association between baseline ctDNA and MRD with imaging biomarkers (TMTV, Dmax, SUVmax, AI features etc).
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
8) Association of CH with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses
Time Frame: from enrollment start to final analyses (15 years)
9) Association of SNPs with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 3 - Tumor tissue analyses
Time Frame: from enrollment start to final analyses (15 years)
1) Association between target antigen surface level and CRR with naked antibodies-based treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before naked antibodies-based therapies.
from enrollment start to final analyses (15 years)
Naked antibodies - Work package 3 (WP3) Task 3 - Tumor tissue analyses
Time Frame: from enrollment start to final analyses (15 years)
2) Association between target antigen surface level and OS, PFS and ORR with naked antibodies based-treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before naked antibodies based-treatment and correlation with biological and imaging predictors. Correlation of CH with PFS, OS and therapy-related toxicities and correlation of SNPs with PFS, OS and therapy-related toxicities.
from enrollment start to final analyses (15 years)
All Work packages
Time Frame: from enrollment start to final analyses (15 years)
1) Prognostic quantitative PET indices: Metabolic Tumor Volume (MTV), Total Glycolytic Volumes (TLG), SUVmax and SUVpeak, other index of tumor dissemination (maximum distance between the lesion, product of distance and MTV, etc.…) and radiomics index.
from enrollment start to final analyses (15 years)
All Work packages
Time Frame: from enrollment start to final analyses (15 years)
2) Association between plasma and lymph nodes microbiome and outcomes (ORR, Complete Response Rate (CRR), PFS, OS) in NMAB-approved treatments.
from enrollment start to final analyses (15 years)
All Work packages
Time Frame: from enrollment start to final analyses (15 years)
3) Evaluation of correlations between immune cell subsets (T-cell subsets, NK cells), immunological clusters, soluble mediators, and clinical efficacy.
from enrollment start to final analyses (15 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Fondazione Italiana Linfomi - ETS

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Riccardo Moia, MD, Divisione di Ematologia, Dipartimento di Medicina Traslazionale Università del Piemonte Orientale, AOU Maggiore della Carità, Novara (Italy)
  • Study Chair: Simone Ferrero, Prof., Ematologia Universitaria, A.O.U. Città della Salute e della Scienza di Torino, Torino (Italy)
  • Study Chair: Rita Tavarozzi, MD, SCDU Ematologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2041

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2041

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 5, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 11, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 17, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 11, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BIO-FIL_MAB

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may contact the FIL board at segreteriadirezione@filinf.it to share invidual-level patients' clinical data analysed for this manuscript (for the avoidance of doubt, no identifiable data, such as name, address, hospital name, date of birth, or any other identifying data, will be shared and should not be requested).

IPD Sharing Time Frame

In compliance with the domestic ethics guideline and applicable legislation, invidual deindentified patients' data underlying the results reported in the publication article (including study protocol, statistical analysis plan and data coding) can be shared until 5 years after the publication of the article.

IPD Sharing Access Criteria

For each data sharing request, it is essential that a proforma (available on request) is completed that describes the general purpose, specific aims, data items requested, analysis plan and acknowledgment of the trial management team. Requests will be reviewed based on scientific merit and ethical principles. Requestors who are granted access to the data will be required to complete a data sharing agreement that will be signed by the requester and FIL.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings